Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Margaretha De Vos

Showing results (1-10 of 57) with videos related to

Pageof 6
Sort By:
Plos One|August 24, 2023
Determining cost and placement decisions for moderate complexity NAATs for tuberculosis drug susceptibility testingAkash Malhotra, Ryan Thompson, Margaretha De Vos, et al.
Plos One|December 26, 2024
Correction: Determining cost and placement decisions for moderate complexity NAATs for tuberculosis drug susceptibility testingAkash Malhotra, Ryan Thompson, Margaretha De Vos, et al.
Medrxiv : the Preprint Server for Health Sciences|July 1, 2024
Optimal processing of tongue swab samples for Mycobacterium tuberculosis detection by the Xpert MTB/RIF Ultra assayGayatri Shankar Chilambi, Robert Reiss, Naranjargal Daivaa, et al.
Microbiology Spectrum|January 28, 2025
Optimal processing of tongue swab samples for <i>Mycobacterium tuberculosis</i> detection by the Xpert MTB/RIF Ultra assayGayatri Shankar Chilambi, Robert Reiss, Naranjargal Daivaa, et al.
The Journal of Molecular Diagnostics : JMD|October 15, 2022
Feasibility, Ease-of-Use, and Operational Characteristics of World Health Organization-Recommended Moderate-Complexity Automated Nucleic Acid Amplification Tests for the Detection of Tuberculosis and Resistance to Rifampicin and IsoniazidAnura David, Margaretha de Vos, Lesley Scott, et al.
Briefings in Bioinformatics|December 28, 2021
Detection of minor variants in Mycobacterium tuberculosis whole genome sequencing dataSander N Goossens, Tim H Heupink, Elise De Vos, et al.
The Cochrane Database of Systematic Reviews|May 18, 2022
Xpert MTB/XDR for detection of pulmonary tuberculosis and resistance to isoniazid, fluoroquinolones, ethionamide, and amikacinSamantha Pillay, Karen R Steingart, Geraint R Davies, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|May 2, 2021
Diagnostic accuracy of the FluoroType MTB and MTBDR VER 2.0 assays for the centralized high-throughput detection of Mycobacterium tuberculosis complex DNA and isoniazid and rifampicin resistanceAnzaan Dippenaar, Brigitta Derendinger, Tania Dolby, et al.
Scientific Reports|February 16, 2020
Extract from used Xpert MTB/RIF Ultra cartridges is useful for accurate second-line drug-resistant tuberculosis diagnosis with minimal rpoB-amplicon cross-contamination riskRouxjeane Venter, Stephanie Minnies, Brigitta Derendinger, et al.
Advances in Pharmacological and Pharmaceutical Sciences|July 9, 2021
Antimycobacterial Activity, Synergism, and Mechanism of Action Evaluation of Novel Polycyclic Amines against <i>Mycobacterium tuberculosis</i>Erika Kapp, Jacques Joubert, Samantha L Sampson, et al.
Pageof 6

Showing results (1-10 of 57) with videos related to

Sort By:
Pageof 6
Plos One|August 24, 2023
Determining cost and placement decisions for moderate complexity NAATs for tuberculosis drug susceptibility testingAkash Malhotra, Ryan Thompson, Margaretha De Vos, et al.
Plos One|December 26, 2024
Correction: Determining cost and placement decisions for moderate complexity NAATs for tuberculosis drug susceptibility testingAkash Malhotra, Ryan Thompson, Margaretha De Vos, et al.
Medrxiv : the Preprint Server for Health Sciences|July 1, 2024
Optimal processing of tongue swab samples for Mycobacterium tuberculosis detection by the Xpert MTB/RIF Ultra assayGayatri Shankar Chilambi, Robert Reiss, Naranjargal Daivaa, et al.
Microbiology Spectrum|January 28, 2025
Optimal processing of tongue swab samples for <i>Mycobacterium tuberculosis</i> detection by the Xpert MTB/RIF Ultra assayGayatri Shankar Chilambi, Robert Reiss, Naranjargal Daivaa, et al.
The Journal of Molecular Diagnostics : JMD|October 15, 2022
Feasibility, Ease-of-Use, and Operational Characteristics of World Health Organization-Recommended Moderate-Complexity Automated Nucleic Acid Amplification Tests for the Detection of Tuberculosis and Resistance to Rifampicin and IsoniazidAnura David, Margaretha de Vos, Lesley Scott, et al.
Briefings in Bioinformatics|December 28, 2021
Detection of minor variants in Mycobacterium tuberculosis whole genome sequencing dataSander N Goossens, Tim H Heupink, Elise De Vos, et al.
The Cochrane Database of Systematic Reviews|May 18, 2022
Xpert MTB/XDR for detection of pulmonary tuberculosis and resistance to isoniazid, fluoroquinolones, ethionamide, and amikacinSamantha Pillay, Karen R Steingart, Geraint R Davies, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|May 2, 2021
Diagnostic accuracy of the FluoroType MTB and MTBDR VER 2.0 assays for the centralized high-throughput detection of Mycobacterium tuberculosis complex DNA and isoniazid and rifampicin resistanceAnzaan Dippenaar, Brigitta Derendinger, Tania Dolby, et al.
Scientific Reports|February 16, 2020
Extract from used Xpert MTB/RIF Ultra cartridges is useful for accurate second-line drug-resistant tuberculosis diagnosis with minimal rpoB-amplicon cross-contamination riskRouxjeane Venter, Stephanie Minnies, Brigitta Derendinger, et al.
Advances in Pharmacological and Pharmaceutical Sciences|July 9, 2021
Antimycobacterial Activity, Synergism, and Mechanism of Action Evaluation of Novel Polycyclic Amines against <i>Mycobacterium tuberculosis</i>Erika Kapp, Jacques Joubert, Samantha L Sampson, et al.
Pageof 6